Dominik Belloin Joins biolog-id’s Board of Directors
Biolog-id, a global leader in the traceability of sensitive therapeutic products, has just co-opted Dominik BELLOIN within the company’s board. He will sit alongside Pierre Lesourd, Jean-Louis Colders, Jacques Simonnet and Jean-Claude Mongrenier.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005699/en/
Graduated from ESSEC and Harvard Business School (MBA), Dominik Belloin began his career at Goldman Sachs in 1987 in New York City, then in London as Associate and then Executive Director of Corporate Finance. He then joined the Bertelsmann Group where he held several senior management positions before becoming CFO of the RTL Group in Luxembourg. In 2000, he was appointed Managing Director of Merrill Lynch with responsibility for investment banking for the media sector in Europe. In 2003, Dominik Belloin became a member of the Executive Committee of the Oddo & Cie Group and took over the management of ODDO Corporate Finance investment banking subsidiary. In 2009, he joined the Kepler Group to participate in the company’s LBO and to create and manage its new investment banking division, Kepler Corporate Finance.
“As part of biolog-id’s evolution, the board of directors is being enriched and welcomes new members whose experience and professional background will help the company to deliver its objectives, both commercial and financial. In this context, Jacques Simonnet, Board member of biolog-id, and I are very pleased to welcome Dominik Belloin. He brings us a leading expertise in the financial and banking fields and, I am sure, will contribute to the implementation of our growth strategy and the development of the company”, says Jean-Claude Mongrenier, Chairman of the Board of Directors.
“Biolog-id provides the human and financial means to accelerate its development. Therefore, I am delighted to be part of this great entrepreneurial adventure and to bring my over 30 years of international experience in finance and mergers-acquisitions”, explains Dominik Belloin.
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and Xerys Invest. Xerys Invest is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PA-MDSLINK-INC25.1.2022 16:02:09 CET | Press release
MDSLink Makes MaGiC™
NY-KROLL25.1.2022 16:02:08 CET | Press release
Kroll Unifies Brand to Reflect Strategic Growth and Vision
NE-ADJUVANCE-TECH25.1.2022 15:37:12 CET | Press release
Dr. Philip Krause to Provide Strategic Advice to Adjuvance
BLUE-OCEAN-ROBOTICS25.1.2022 15:04:14 CET | Press release
UVD Robots Joins Ecolab’s Global Infection Prevention Offerings to Fight Hospital Acquired Infections
MA-ALVARIA25.1.2022 15:02:43 CET | Press release
Alvaria Adds Real Time Intelligent AI Capability to Optimize Enterprise Contact Center Employees
NC-INTL-ZINC-ASSOCIATION25.1.2022 15:02:43 CET | Press release
The International Zinc Association Announces Hindustan Zinc Ltd’s CEO/Full Time Director, Arun Misra, as New Chairman
DE-CSC25.1.2022 15:02:42 CET | Press release
CSC Research Finds Third Parties Continue to Lay Groundwork for Malicious Activity Among Thousands of COVID-Related Domains
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom